Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-914 in Moderate to Severe Atopic Dermatitis
2023-510238-10-00Phase 2Completed
- Sponsor
- Q32 Bio
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Bempikibart with Placebo (2 arms). Started Apr 2024; status: completed.
02
Drugs
bempikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-510238-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510238-10-00.